What the UK’s new clinical trials regime means for pharmacy practice and patient safety Pharmacists will be central to the impact of the new clinical trial regime, which is aimed to streamline regulatory timelines.…
PJ view: Patients deserve a regulatory system built to keep them safe as oral semaglutide launches Regulators have taken welcome steps to tackle counterfeit weight-loss medicines, but patients cannot be left to police this market alone.…
GPhC launches campaign on risk of fake online pharmacies following launch of oral semaglutide The General Pharmaceutical Council has created posters and videos to educate patients on how to spot a fake online pharmacy.…
Everything you need to know about GLP-1s for weight loss From semaglutide to tirzepatide, this article collates the latest information on pharmacological weight-loss treatments, including evidence and best practice for their use.…
Pharmacy regulator warns against promotion of prescription weight-loss medicines A notice has reminded businesses that they cannot advertise prescription-only medicines or prescription-only medical treatments to the public.…
Staying safe with online pharmacies: what patients and providers need to know about weight-loss prescribing What pharmacy staff and patients should know about weight-loss prescribing, as regulatory communications continue to highlight concerns related to online weight-loss services.…
Clinical decision support tools in pharmacy practice Practical advice for pharmacy teams on the current use of clinical decision support tools, as well as their benefits and limitations.…
Pharmacy research: driving safer outcomes in substance misuse Research offers a crucial opportunity in shaping healthcare policy and practice, particularly in the developing landscape of substance misuse.…
Coroner flags lack of clarity around expanded role of community pharmacists under Pharmacy First A coroner has questioned methotrexate guidance after a patient died after developing methotrexate-induced pancytopenia and pneumonia.…
The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought As the use of glucagon-like peptide-1 receptor agonists increases, so must our awareness of patients who have an eating disorder or who are at risk of developing one.…
